(Q33904384)

29 July 2017

1 reference

title

The emerging role of radioimmunotherapy in haematological malignancies (English)

1 reference

29 July 2017

Illidge TM

1

1 reference

29 July 2017

Johnson PW

series ordinal

2

1 reference

29 July 2017

language of work or name

English

0 references

publication date

1 March 2000

1 reference

British Journal of Haematology

29 July 2017

published in

1 reference

29 July 2017

volume

108

1 reference

29 July 2017

issue

4

1 reference

29 July 2017

page(s)

679-688

1 reference

Radioimmunotherapy strategies for non-Hodgkin's lymphomas

29 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.01926.X

Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.01926.X

Maximum-tolerated dose, toxicity, and efficacy of (131)I-Lym-1 antibody for fractionated radioimmunotherapy of non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.01926.X

The TRAIL to selective tumor death

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.01926.X

Targeting, dosimetry, and radioimmunotherapy of B-cell lymphomas with iodine-131-labeled LL2 monoclonal antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.01926.X

Antibodies stage a comeback in cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.01926.X

A phase 1a clinical trial of LYM-1 monoclonal antibody serotherapy in patients with refractory B cell malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.01926.X

Imaging, dosimetry, and radioimmunotherapy with iodine 131-labeled anti-CD37 antibody in B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.01926.X

Radioimmunotherapy of B-cell lymphoma with [131I]anti-B1 (anti-CD20) antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.01926.X

Radioimmunotherapy of lymphoma: a UC Davis experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.01926.X

Mouse/human chimeric monoclonal antibody in man: kinetics and immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.01926.X

IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.01926.X

Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.01926.X

Total body irradiation for stage II-IV non-Hodgkin's lymphoma: ten-year follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.01926.X

Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.01926.X

The sensitivity of lymphocytes to ionising radiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.01926.X

Human anti-mouse antibody suppression with cyclosporin A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.01926.X

Novel technology for detection of genomic and transcriptional alterations in pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.01926.X

10.1046/J.1365-2141.2000.01926.X

21 January 2018

Identifiers

DOI

1 reference

29 July 2017

1 reference